Stayble Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	8.55	13.03	24	24.95	12.14	14.98
Other Operating Expenses	-0.06	-	-	-0	-0	-
Operating Expenses	8.64	13.18	24.1	24.95	12.14	14.98
Operating Income	-8.64	-13.18	-24.1	-24.95	-12.14	-14.98
Interest Expense	-0.05	-0.05	-0.04	-0.03	-0.06	-0.4
Interest & Investment Income	0.22	0.43	0.26	0.03	0.03	-
Currency Exchange Gain (Loss)	-	-	-	0.42	0.08	-0.11
Other Non Operating Income (Expenses)	0.05	0.39	0.15	-	-	-
Pretax Income	-8.42	-12.42	-23.74	-24.53	-12.09	-15.49
Net Income	-8.42	-12.42	-23.74	-24.53	-12.09	-15.49
Net Income to Common	-8.42	-12.42	-23.74	-24.53	-12.09	-15.49
Shares Outstanding (Basic)	54	38	26	14	14	7
Shares Outstanding (Diluted)	54	38	26	14	14	7
Shares Change (YoY)	54.55%	47.05%	86.06%	-	100.00%	70.26%
EPS (Basic)	-0.16	-0.33	-0.92	-1.77	-0.87	-2.24
EPS (Diluted)	-0.16	-0.33	-0.92	-1.77	-0.87	-2.24
EBITDA	-	-13.03	-24	-	-	-
D&A For EBITDA	-	0.15	0.1	-	-	-
EBIT	-8.64	-13.18	-24.1	-24.95	-12.14	-14.98
Revenue as Reported	0.05	0.39	0.15	0.29	0.01	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.